AVALOX ® - Moxifloxacin

AVALOX ® is a drug based on Moxifloxacin Hydrochloride

THERAPEUTIC GROUP: Antimicrobials - antibiotics for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications AVALOX ® - Moxifloxacin

AVALOX ® is indicated in the treatment of infections caused by microorganisms sensitive to Fluoroquinolones, and in particular to Moxifloxacin, when the common antibiotic therapy is ineffective.

This antibiotic has proven to be effective above all in infectious diseases of the respiratory system.

Mechanism of action AVALOX ® - Moxifloxacin

AVALOX ® is a medicinal product based on Moxifloxacin, an antibiotic belonging to the third generation Fluoroquinolones category, therefore effective against a high number of microbial species and characterized by particularly advantageous pharmacokinetic properties.

Taken orally, in fact, Moxifloxacin is rapidly absorbed at the intestinal level with a bioavailability greater than 90%, to be subsequently metabolized at the hepatic level and excreted both via the kidney and minimally also through the biliary and fecal route.

The bacteriostatic activity of the active principle is evidently due to the ability to bind and inhibit bacterial enzymes involved in DNA replication mechanisms such as DNA gyrase and DNA topoisomerase, thus determining a control action on bacterial proliferation mechanisms.

Despite the good therapeutic response observed in the various studies and clinical experience, international trials denounce the growing appearance of multiresistant microbial strains, equipped with efflux pumps, inactivating cytoplasmic enzymes or biological target mutation systems, which prevent the active ingredient from reaching therapeutically effective concentrations within the bacterial cytosol.

Studies carried out and clinical efficacy

MOXIFLOXACINE AND PULMONITES ACQUIRED IN THE COMMUNITY

Clinical trial demonstrating the efficacy and safety of Moxifloxacin in the treatment of pneumonia acquires in communities normally resistant to Beta-lactam-based therapy.

MOXIFLOXACINE AND ABDOMINAL INFECTIONS

PROMISE studies that demonstrate how Moxifloxacin can be effective in the treatment of intra-abdominal infections, like other clinically most used antibiotics such as escapenem.

PSEUDOUVEITE FROM MOXIFLOXACINA

This side effect could be determined by hypersensitivity reactions to the drug.

Method of use and dosage

AVALOX ®

Moxifloxacin 400 mg coated tablets.

Generally the use of one tablet of AVALOX ® per day is effective in coping with most clinical conditions for which therapy with Moxifloxacin is indicated.

In order for the therapy to be effective, avoiding possible re-exacerbations of symptoms, it would be necessary to prolong the intake of the drug for at least 48 hours from the regression of symptoms.

Warnings AVALOX ® - Moxifloxacin

AVALOX ® therapy should be preceded and supervised by your doctor, in order to monitor its efficacy and safety, thus safeguarding the patient's state of health.

Particular caution should be reserved for:

Patients with enzyme deficiency of glucose 6 phosphate dehydrogenase, given the increased risk of hemolytic episodes;
Patients in the pediatric age or under development, due to the increased risk of tendinitis and arthropathy;
Patients with neurological and cardiovascular diseases, due to the possible re-exacerbation of symptoms;
Patients with lactase enzyme deficiency, glucose / galactose malabsorption syndrome, lactose intolerance, due to the presence of lactose among the excipients of the drug;
Atopic patients, due to the risk of hypersensitivity reactions to the drug;

It is also recommended to avoid direct exposure to ultraviolet rays after taking Moxifloxacin.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to characterize the safety profile of Moxifloxacin for fetal health and the ability of the active ingredient to concentrate in breast milk in therapeutic concentrations, it is recommended to avoid taking AVALOX ® during pregnancy and in the subsequent breastfeeding period.

Interactions

In order to preserve the therapeutic efficacy and safety of Moxifloxacin, the patient receiving AVALOX ® should avoid the simultaneous intake of:

Foods, supplements and drugs containing divalent metals, given the ability to form chelating complexes, responsible for reducing the therapeutic efficacy of the antibiotic;
Tiazanidine, methotrexate, theophylline, xanthine and phenytoin due to the altered tubular secretion induced by Fluoroquinolone and the consequent strengthening of biological and collateral effects;
Oral anticoagulants, due to the increased anticoagulant activity induced by the antibiotic.

Contraindications AVALOX ® - Moxifloxacin

The use of AVALOX ® is contraindicated in patients who are hypersensitive to the drug or to one of its excipients, in patients with serious heart conditions or with kidney diseases.

Undesirable effects - Side effects

Treatment with AVALOX ® could lead to the appearance of:

Gastrointestinal symptoms such as diarrhea, nausea, vomiting, abdominal pain and in severe cases clostridium difficile infection;
Neurological symptoms such as headache, irritability, drowsiness and rarely seizures;
Hypertransaminasemia and alterations in renal function;
Osteo-articular disorders.